QDEL — Stock Film
STOCK FILMSCENE 1/11QDEL · $16.58
Stock Expert AI presents
QDEL
QuidelOrtho Corporation
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
QuidelOrtho Corporation. A quick introduction.

On the stock market since 1991, it operates in the world of health and science. It has 6,500 employees. Now — the numbers.

on the stock market since 1991
6,500 employees
$1.1B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.4.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 13% a year over the last 4 years. Red columns mark years that ended in a loss.

$1.7B
2021
$3.3B
2023
$3B
2023
$2.8B
2024
$2.7B
2025
In the vault right now:
$0
DEBT: $2.8B
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
38
weak

Clearly below the class average.

FINANCIAL STRENGTH
48
weak

Clearly below the class average.

VALUATION
59
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
46
weak

Clearly below the class average.

PRICE MOMENTUM
40
weak

Clearly below the class average.

WORTH WATCHING

Business Quality: Profit power and business quality trail similar companies in the sector.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Costs eat into the margin4/10
WORTH WATCHING

Cost Efficiency: As sales grow, profit fails to keep the same pace.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 13% a year on average.

2
THE BRIGHT SIDE · 2/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 87 buys and 68 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
The losses continue

A loss of $1.1B against $2.7B in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

3
THE RISKS · 3/3
The price sits above analysts’ target

The stock trades 26% above the average analyst price target.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, QDEL sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: QDEL has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film